<DOC>
	<DOCNO>NCT00003814</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know eflornithine effective therapy treat bladder cancer . PURPOSE : Randomized phase III trial determine effectiveness eflornithine treat patient newly diagnose recurrent bladder cancer .</brief_summary>
	<brief_title>Eflornithine Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether treatment eflornithine effective prevent recurrence tumor transurethral resection patient low grade , superficial transitional cell carcinoma bladder . II . Determine incidence severity toxicity associate long-term use drug patient population . OUTLINE : This randomize , double blind , multicenter study . Patients stratify accord disease status ( newly diagnose vs recurrent ) , clinical stage ( Ta v T1 ) , grade ( G1 v G2 ) , focus ( multifocal v unifocal ) . Patients receive either oral eflornithine placebo daily . Treatment continue 1 year absence disease progression unacceptable toxicity . Patients follow every 3 month first 2 year , every 6 month third year , annually fourth year . PROJECTED ACCRUAL : A total 450 patient ( 225 per arm ) accrue study within 1.5 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm low grade ( grade 1 2 ) , superficial ( stage Ta T1 ) transitional cell carcinoma ( TCC ) bladder Newly diagnose recurrent All visible tumor must resect within past 12 week Standard clinical management determine expectant observation without surgery , intravesical therapy , systemic therapy No prior upper tract TCC No history grade 3 TCC , carcinoma situ include severe dysplasia , nonTCC histology , TCC great equal T2 No involvement upper urinary tract prior time initial tumor resection Abdominal CT scan , IVP , retrograde pyelogram within past 3 month rule upper urinary tract tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy within past 5 year concurrent malignancy except nonmelanomatous skin cancer carcinoma situ cervix No clinically significant hearing loss ( i.e. , hearing loss effect everyday life and/or wear hear aide ) No significant medical psychiatric condition PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior growth factor No concurrent growth factor Chemotherapy : No prior systemic chemotherapy bladder cancer No concurrent intravesical therapy At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 4 week since prior high dose steroid prednisone No concurrent high dose steroid No concurrent prednisone equivalent excess 10 mg/day Radiotherapy : No prior radiotherapy bladder cancer At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 4 week since prior carbamazepine experimental drug No concurrent carbamazepine experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>